Kineret in the Treatment of Rheumatoid Arthritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Freiburg, Germany
- Swedish Orphan Biovitrum Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Informed consent by the patient
- Rheumatoid arthritis
- Previous methotrexate therapy with inadequate response
Exclusion Criteria:
- Pregnancy
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease Activity Score 28 (DAS28)
Time Frame: 0-52 weeks
|
The DAS28 measures the progress and improvement of Rheumatoid Arthritis.
DAS28 values range from 2.0 to 10.0 while higher values mean a higher disease activity.
A DAS 28 below the value of 2.6 is interpreted as Remission.
Both the number of joints with tenderness upon touching and swelling are counted.
In addition, the erythrocyte sedimentation rate is measured.
Also, the patient makes a subjective assessment of disease activity during the preceding 7 days on a scale between 0 and 100, where 0 is "no activity" and 100 is "highest activity possible".
|
0-52 weeks
|
|
ACR response
Time Frame: 0-52 weeks
|
The ACR (American College of Rheumatology) Criteria measures the effectiveness of treatments for Rheumatoid Arthritis.
The ACR is reported as % improvement, comparing disease activity at two discrete time points.
|
0-52 weeks
|
|
Health Assessment Questionnaire
Time Frame: 0-52 weeks
|
The patients will at each visit complete a questionnaire about their health status and the impairment in usual activities due to the rheumatoid disorder.
|
0-52 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Stefan Zeitler, MD, Swedish Orphan Biovitrum GmbH
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KIRA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.